



Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

TB is a global pandemic

Tuberculosis (TB) is a global disease, found in every country in the world, and is the leading infectious cause of death worldwide.

In 2018, 10 million people fell ill from TB and 1.5 million died. TB is an airborne disease that can be spread by coughing or sneezing and is the deadliest infectious disease in the world.

TB is responsible for economic devastation and feeds a cycle of poverty and illness that entraps families, communities and even entire countries. Among the most vulnerable are women, children and people living with HIV/AIDS.

There is growing resistance to available drugs, which means the disease is becoming more deadly and difficult to treat. There were about half a million cases of drug-resistant TB last year.

New TB treatments are needed

Today's TB treatments take too long to cure, are too complicated to administer, and can be toxic. People with TB must take drugs from 6 months to 2 years or longer – or risk developing more difficult to treat drug-resistant TB.

The cost of curing drug-resistant TB can be staggering, posing a significant challenge to governments, health systems and other payers.

In August 2019, TB Alliance received approval for a new treatment for highly drug-resistant TB. This drug is only the third new anti-TB drug approved for use in more than 40 years, as well as the first to be developed and registered by a not-for-profit organization.

Our pipeline

TB Alliance's mission is to develop better, faster and affordable TB cures. Before TB Alliance was established in 2000, there were no new TB drugs in clinical development.

Today, TB Alliance manages the largest pipeline of new TB drugs in history and has advanced multiple products to market. Our goal is to introduce new treatments that will significantly impact the TB pandemic.

How we operate



TB Alliance is a not-for-profit Product Development Partnership (PDP), an organizational model established to accelerate the development of new technologies to fight public health diseases for which market incentives are lacking. As a PDP, TB Alliance builds partnerships between the public, private, academic and philanthropic sectors to drive the development of new TB treatments.

New TB treatment introduced



In August 2019, TB Alliance received approval from a stringent regulatory authority for the first-ever approved cure for highly drug-resistant forms of TB, including extensively drug-resistant TB (XDR-TB)—the deadliest form of TB—and the first approval for a drug regimen in more than 40 years.

New TB medicines for children



TB Alliance and partners have introduced improved child-friendly TB medicines. More than one million treatment courses have now been ordered by 90+ countries. These quality-assured, affordable treatments come in the correct doses and are improved formulations of proven TB medicines. Dissolvable in water, they are fruit-flavored, making it easier for caregivers to administer and for children to take.

Engaging with communities



TB Alliance is accelerating the global TB response through innovative scientific, strategic and community-based initiatives. Importantly, these initiatives include partnerships with people with TB and impacted communities, empowering them with knowledge and skills that accelerate the pace, promise and capacity of TB research.

Our commitment

TB Alliance can only achieve its mission if new, faster-acting and better TB cures are adopted, available and affordable to those who need them. This commitment—our “AAA Mandate”—is TB Alliance’s explicit pledge to ensure that any new TB treatments developed will be used to benefit people suffering from TB and to have maximum impact on the pandemic.

The promise of new cures

Our ultimate vision is to have a transformative impact on the disease by introducing ultra-short, simple and affordable TB regimens that work in virtually all people with tuberculosis. A sustainable pipeline of combination treatments with such broad utility would have a major impact on the global epidemic, saving millions of lives.

The potential benefits of new TB cures include:

- Shorter, simpler and safer treatment, with improved adherence and fewer side effects, reducing the burden of treatment to health care systems, TB programs and patients
- Ability to treat both drug-sensitive and drug-resistant disease with the same regimen, simplifying and enabling the scale-up of therapy globally
- Affordable treatment for drug-resistant TB, at a fraction of the cost of current treatment efforts
- Compatibility with HIV/AIDS medications
- Improved treatment outcomes and patient experience
- Safe and effective TB treatments designed specifically for children

References

1. World Health Organization (WHO). *Global TB Report 2018*.

Without new and improved TB treatments, we cannot defeat this deadly disease.